The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2022Evaluating the Efficacy of a mGluR5 Modulator in Preclinical Models of Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is one of many neurodegenerative diseases that are characterized by the buildup of misfolded protein aggregates in the brain. Preclinical data suggest that...
-
Clinical Discovery Awards, 2005Executive, ADL, and Cholinergic Functions in PD
Parkinson's disease is a disorder that is most known for motor impairments of tremor, slowness in moving, and loss of balance. Patients with Parkinson's disease also suffer from non-motor symptoms...
-
Therapeutic Pipeline Program, 2018Development of ALK4290 as a Novel Parkinson's Therapeutic
Study Rationale:
There is clear evidence that the immune system plays an important role in the development and progression of Parkinson's disease. Novel therapies targeting the recruitment of immune... -
2022: Accelerated Therapeutics Program, 2024(SUPPLEMENT) Innovative Therapies for Parkinson’s Disease Through a Novel, Unexploited Gene Expression Mechanism Rooted in Human Genetics Enabling a Precision-medicine Approach
Study Rationale: Parkinson’s disease (PD) and Alzheimer’s disease (AD) are neurodegenerative disorders caused by an accumulation of protein aggregates that leads to cell death. Genetic studies suggest...
-
Clinical Intervention Awards, 2012A Randomized Controlled Trial of Neurocognitive and Supportive Therapy Interventions for Individuals with Parkinson’s DiseaseObjective/Rationale: In the twenty-first century the motor symptoms of Parkinson’s disease (PD) are typically well-managed. The neurocognitive symptoms of Parkinson’s disease often result in...
-
Fall 2020 RFA: Therapeutic Pipeline Program-Pre-Clinical, 2022Targeting Colony-stimulating Factor 1 Receptor (CSF1R) to Modify Disease Progression in Preclinical Experimental Models of Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by pronounced neuroimmune dysfunction. Although the disease is very common, no therapy is available...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.